VANCOUVER and TORONTO, Canada — January 8, 2018 - Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, has received support of up to $350,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). In addition, The Centre for Drug Research and Development (CDRD) and MaRS Innovation have contributed follow on funding to the Company’s existing convertible note.
Zucara recently defined its lead drug candidate, ZT-01, and ...
VANCOUVER and TORONTO, Canada (November 3, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, announced it has received a $525,000 investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI).
This unique deal brings together three organizations mandated with enabling the growth of Canada’s health sciences sector. Each partner brings its respective strengths to the table: capital, ...
UTEST graduate company building a versatile, smart, modular power bar
We've all been there: You reach over behind your TV to plug in yet another device to find your power bar’s out of available outlets. You wonder why your electricity bill’s so high and want to know which appliance is the culprit. You forget to turn something off (or did you?) and you’re already halfway to a meeting.
Knitt Labs, Inc. has developed KnittBar to solve these frustrating problems for those who are ...
MaRS Innovation portfolio company completing Phase 1 human clinical trial of drug to prevent dermal scarring
VANCOUVER (February 16, 2016) — Accel-Rx Health Sciences Accelerator (Accel-Rx), a Centre of Excellence for the Commercialization of Research (CECR), and its partner BDC Capital today announced their second joint investment in ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis).
Accel-Rx and BDC Capital, and other investors including MaRS Innovation, have invested a total of $2 million in ScarX. This investment will ...
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by Dr. Raphael Hofstein, MaRS Innovation's president & CEO, and Elizabeth Monier-Williams, director of marketing and communications.
The article explores the way research focused on discovery and commercialization are often viewed or positioned as competitors within the funding ecosystem and the need to align their goals:
The time of Canada’s French and English solitudes may be past, as Governor General Michaëlle Jean notably stated when she took office ...
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Dr. Raphael Hofstein.
The article explores the role life sciences assets, financing and talented management--the three Ms--must play in revitalizing Canada's biotechnology sector:
At the close of the 20th century, Canada was perceived as a key contributor to the success of the global biotech voyage.
You know what happened next: the mechanisms to fund early ventures collapsed together with the collapse of the ...
The University of Toronto Early-Stage Technology (UTEST) program helps U of T students, recent grads or professors to take their ideas to market.
Successful applicants get mentoring, funding and work space over a 12-month period as they advance their ideas. The program is co-managed by MaRS Innovation and the University of Toronto.
In a U of T "Spotlight on Startups" news article, Brianna Goldberg spoke with Mike Betts and Kurtis Scissons, UTEST co-directors, on what makes for a great applicant.
Here's an excerpt:
What are ...
Techvibes, a publication dedicated to covering latest trends in start-up culture and social and mobile news, covered the University of Toronto Early-Stage Technology (UTEST) program's call for applications in an online article on March 1, 2014.
Applications for UTEST's third cohort are open until April 17, 2014. Co-directors Kurtis Scissons and Mike Betts will work with selected applicants for a period of twelve months to guide their idea to market. Successful applicants receive work space for a year, mentorship, $30,000 in funding ...